HIT Consultant
OCTOBER 25, 2022
Contributing factors to this included larger trial sizes, the need to assess health technology, the requirement to provide data on comparative drugs’ effectiveness, and most importantly the high failure rate. A study in 2020 concluded that the estimated median capitalized research and development cost per product was $985 million.
Bill Of Health
OCTOBER 15, 2021
The COVID-19 pandemic has laid bare the lack of regulation for the sharing of intellectual property (IP) and technology needed for an effective and equitable response to the crisis. Multinational pharmaceutical companies have declined collaboration with C-TAP and with the WHO mRNA hubs on COVID-19 vaccines. By Ellen ‘t Hoen.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bill Of Health
SEPTEMBER 20, 2022
New mRNA vaccines, underpinned by decades of public investment , had been authorized by global regulators. Dose shortages elevated the role of pharmaceutical executives. The answer to one of the most important public health questions of our time — who gets access to vaccines? — Private decisions did not match public health need.
Bill Of Health
MARCH 25, 2022
Each month, members of the Program On Regulation, Therapeutics, And Law (PORTAL) review the peer-reviewed medical literature to identify interesting empirical studies, policy analyses, and editorials on health law and policy issues. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
Healthcare ECONOMIST
NOVEMBER 14, 2022
By supporting decision-making on the development, authorisation and surveillance of medicines, a wide range of stakeholders will benefit, from patients and healthcare professionals to health technology assessment bodies and the pharmaceutical industry. Arlett et al. The DARWIN EU advisory board members are listed here.
Bill Of Health
APRIL 5, 2023
That these individuals are at the receiving end of these technologies is explicitly emphasized in the publicity of some reproductive health technology companies. The post Reproductive Health Technologies: From Design Feature to Defect appeared first on Bill of Health.
Health Advances
MAY 4, 2022
A large and aging population advanced IT infrastructure, and a single national healthcare system are among the features that will make Japan and South Korea ideal candidates to adopt digital health technologies at scale. Telemedicine in Korea is regulated by Medical Service Act and Personal Information Protection Act.
Expert insights. Personalized for you.
97 
Let's personalize your content